Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Identifieur interne : 001204 ( Ncbi/Checkpoint ); précédent : 001203; suivant : 001205Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Auteurs : William Bara-Jimenez [États-Unis] ; Francesco Bibbiani ; Michael J. Morris ; Tzvetelina Dimitrova ; Abdullah Sherzai ; Maral M. Mouradian ; Thomas N. ChaseSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- methods : Drug Evaluation.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Organic Chemicals, Serotonin 5-HT1 Receptor Agonists, Severity of Illness Index, Treatment Outcome.
Abstract
Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5-HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3-week, double-blind, placebo-controlled, proof-of-concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa-induced dyskinesias and prolonged its antiparkinsonian response (P < or = 0.05). Under the conditions of this study, our findings suggest that 5-HT1A receptor stimulation in levodopa-treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT1A agonists may be useful as levodopa adjuvants in the treatment of PD.
DOI: 10.1002/mds.20370
PubMed: 15791634
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003097
- to stream PubMed, to step Curation: 003097
- to stream PubMed, to step Checkpoint: 003149
- to stream Ncbi, to step Merge: 001204
- to stream Ncbi, to step Curation: 001204
Links to Exploration step
pubmed:15791634Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.</title><author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name></author><author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J" last="Morris">Michael J. Morris</name></author><author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name></author><author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name></author><author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M" last="Mouradian">Maral M. Mouradian</name></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20370</idno><idno type="RBID">pubmed:15791634</idno><idno type="pmid">15791634</idno><idno type="wicri:Area/PubMed/Corpus">003097</idno><idno type="wicri:Area/PubMed/Curation">003097</idno><idno type="wicri:Area/PubMed/Checkpoint">003149</idno><idno type="wicri:Area/Ncbi/Merge">001204</idno><idno type="wicri:Area/Ncbi/Curation">001204</idno><idno type="wicri:Area/Ncbi/Checkpoint">001204</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.</title><author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name></author><author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J" last="Morris">Michael J. Morris</name></author><author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name></author><author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name></author><author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M" last="Mouradian">Maral M. Mouradian</name></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Evaluation (methods)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Organic Chemicals</term><term>Parkinson Disease (drug therapy)</term><term>Serotonin 5-HT1 Receptor Agonists</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Organic Chemicals</term><term>Serotonin 5-HT1 Receptor Agonists</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5-HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3-week, double-blind, placebo-controlled, proof-of-concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa-induced dyskinesias and prolonged its antiparkinsonian response (P < or = 0.05). Under the conditions of this study, our findings suggest that 5-HT1A receptor stimulation in levodopa-treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT1A agonists may be useful as levodopa adjuvants in the treatment of PD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J" last="Morris">Michael J. Morris</name><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M" last="Mouradian">Maral M. Mouradian</name><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001204 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001204 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:15791634
|texte= Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:15791634" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |